1. A multi-center study of high dose Aldesleukin (Proleukin® (HD IL-2) + Vemurafenib Zelboraf® ) therapy in patients with BRAFV600 mutation positive metastatic melanoma (proclivity 01) Clark, Joseph; Flaherty, Lawrence; Ernstoff, Marc; Koon, Henry; Milhem, Mohammed; Militello, Gerald; Agarwala, Sanjiv; Curti, Brendan; Cranmer, Lee; Lao, Christopher; Logan, Theodore; Lutzky, Jose; Rudrapatna, Venkatesh; Daniels, Gregory; Taback, Bret; Aung, Sandra; Lowder, James; Lawson, David 2014 Articles Melanoma--TreatmentMetastasisOncology
2. Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin® (HD IL-2) and Ipilimumab Yervoy® ) in patients with metastatic melanoma (proclivity 02) Patel, Sapna; Milhem, Mohammed; Hallmeyer, Sigrun; Daniels, Gregory; Cranmer, Lee; Taback, Bret; Flaherty, Lawrence; Aung, Sandra; Lowder, James; Sharfman, William 2014 Articles MetastasisMelanoma--TreatmentOncology
3. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma Clark, Joseph I.; Singh, Jatinder; Ernstoff, Marc S.; Lao, Christopher D.; Flaherty, Lawrence E.; Logan, Theodore F.; Curti, Brendan; Agarwala, Sanjiv S.; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L.; Aung, Sandra; Lawson, David H. 2018 Articles Cancer--ImmunotherapyInterleukin-2Melanoma--TreatmentEnzyme inhibitors